Hutchison China MediTech Limited
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Hutchison China MediTech Limited
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Chi-Med has revised its commercial rights agreement in China for Elunate (fruquintinib) with Lilly to seize China’s rapid growth trajectory, CEO Christian Hogg tells Scrip.
Public Company Edition: June has seen 14 initial public offerings by drug developers (and one big biopharma funder) after there were only 15 from January through May – and the month isn’t over yet. Follow-on and other offerings also are hitting the market at a rapid pace.
Portfolio management is high on innovative drug maker’s mind amid aftermath of coronavirus outbreak.
- OTC, Consumer
- Other Names / Subsidiaries
- Hutchison Whampoa Sinopharm Pharmaceuticals Company Limited
- Hutchison MediPharma Limited